Market News & Trends
NeoVac Announces Positive Results Demonstrating Superior Safety Profile of Next-Generation mRNA-LNP Vaccine Platform
NeoVac recently announced positive results from first-in-human Phase I/II clinical study of NeomiVac, its investigational mRNA-LNP COVID-19 vaccine candidate. The clinical findings, now publicly available as…
SynGenSys Introduces Liver.SET Synthetic Promoter Library for Liver-Specific Gene Expression for In Vivo Gene Therapies
SynGenSys recently announced the launch of its Liver.SET library of liver-specific synthetic promoters. Developed using SyngenSys’ proprietary informatics and computational design platform, the Liver.SET library…
Evogene & Shanghai Lishan Biopharmaceuticals Announce Exclusive Licensing Agreement for a Microbiome-Based Therapeutic for Renal & Lung Cancer
Evogene Ltd. and Shanghai Lishan Biopharmaceuticals Co., Ltd. recently announced that Biomica Ltd., Evogene’s subsidiary, and Lishan Biotech entered into an exclusive worldwide licensing agreement for…
Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination With Pasritamig
Coherus Oncology, Inc. recently announced a clinical supply agreement with Johnson & Johnson to evaluate tagmokitug (CHS-114), Coherus Oncology’s investigational anti-CCR8 cytolytic monoclonal antibody, in…
Bracco Enters Cell Therapy Manufacturing With Cell Selection & Activation Technologies
Bracco Imaging recently announced its first expansion into the cell therapy space, driven by its expertise and newly developed applications of its long-established microbubble technology. Bracco's…
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc. recently announced the first patient has been dosed in the Phase 1/2 clinical trial (NCT07300241) evaluating NEO-811, a novel investigational molecular glue degrader, in…
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection
Quanterix Corporation recently announced it has submitted a 510(k) premarket notification to the US FDA for a multi-analyte algorithmic blood test for Alzheimer’s disease (AD).…
Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies
Cellares recently announced a collaboration with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative Medicines Accelerator (IMA) to automate manufacturing and…
Alzheon Reports Plasma Biomarker Results From Phase 3 & 2 Studies, Validating First-in-Class Mechanism of Action & Underscoring Benefits in Cognition, Function & Brain Volume Protection in Alzheimer’s Patients
Alzheon, Inc. recently announced plasma biomarker analyses from its APOLLOE4 Phase 3 and Phase 2 clinical studies of valiltramiprosate/ALZ-801. New results offer robust evidence supporting the…
Sanofi’s Venglustat Met All Primary Endpoints in Phase 3 Study of Type 3 Gaucher Disease
Positive results from the LEAP2MONO Phase 3 study (clinical study identifier: NCT05222906) demonstrated that venglustat met the primary and three out of four key secondary…
MGS Launches A.i.r. Platform, Delivering New Levels of Design Flexibility for Auto-Injectors
MGS recently announced the launch of the A.i.r. Platform, a groundbreaking customizable auto-injector platform designed to meet the diverse needs of patients, Pharmaceutical innovators and…
Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
Piramal Pharma Solutions recently announce the successful development, scale-up, and commercialization of a tablet-in-capsule drug delivery system at its drug product facilities in Pithampur and Ahmedabad,…
PhaseV Launches AI-Powered Enrollment Lab: Eliminating Guesswork & Grounding Study Design in Clinical Reality
PhaseV recently announced the launch of its new Enrollment Lab solution at the 17th Annual SCOPE Summit. A high-impact addition to the PhaseV ClinOps platform, this…
Ardena Completes Divestment of its Södertälje Drug Substance Site in Sweden to Nanologica
Ardena recently announced it has completed the divestment of its drug substance (API) site in Södertälje, Sweden, to Nanologica AB. The business will operate as…
Vetter Pharma to Build New Manufacturing Site in Germany
Vetter Pharma has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany. This strategic investment marks a significant…
ENA Respiratory Announces Dosing of First Participants in Phase II Study of Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
ENA Respiratory recently announced it has dosed the first participants in its Phase II community study of INNA-051, (with the first participant dosing now completed).…
Boehringer Ingelheim’s Investigational Asset Delivers Proteinuria Reduction in Phase II Kidney Trial
Boehringer Ingelheim today announced results from a 12-week Phase II clinical trial evaluating apecotrep (BI 764198), an oral, potential first-in-class, non-immunosuppressive TRPC6 inhibitor for people…
Halo Pharma to Become a Stand-Alone Drug Product Contract Development & Manufacturing Organization
Halo Pharma, a leading CDMO specializing in drug product pharmaceutical development and manufacturing services, will become a stand-alone business as a result of the sale…
Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic in Patients with Elevated Lp(a)
Argo Biopharmaceutical Co., Ltd. recently announced the first patient has been dosed in a global Phase 2b clinical trial sponsored by Novartis evaluating DII235, also…
Vortex Biotech Opens New State-of-the-Art Laboratory at Manchester Science Park
Vortex Biotech Holdings Limited has announced the opening of its advanced laboratory facilities at Manchester Science Park. The new site significantly enhances the company’s R&D…
